Article
Medicine, Research & Experimental
Hui Hua, Jiajia Zeng, Haixin Xing, Yuxin He, Linyu Han, Nasha Zhang, Ming Yang
Summary: This study systematically evaluated the role of genetic variants in A-to-I editing genes on the prognosis of NSCLC patients receiving EGFR-TKIs therapy. The researchers identified several SNPs in the ADAR gene that were significantly associated with patient prognosis and found that silencing ADAR enhanced the sensitivity of NSCLC cells to gefitinib. These findings highlight the importance of A-to-I RNA editing in drug resistance and suggest ADAR as a potential therapeutic target for unresectable NSCLC.
Article
Chemistry, Medicinal
Meredith S. Eno, Jason D. Brubaker, John E. Campbell, Chris De Savi, Timothy J. Guzi, Brett D. Williams, Douglas Wilson, Kevin Wilson, Natasja Brooijmans, Joseph Kim, Aysegul Ozen, Emanuele Perola, John Hsieh, Victoria Brown, Kristina Fetalvero, Andrew Garner, Zhuo Zhang, Faith Stevison, Rich Woessner, Jatinder Singh, Yoav Timsit, Caitlin Kinkema, Clare Medendorp, Christopher Lee, Faris Albayya, Alena Zalutskaya, Stefanie Schalm, Thomas A. Dineen
Summary: While EGFR tyrosine kinase inhibitors have revolutionized the treatment of NSCLC, the development of resistance mutations remains a challenge. This study introduces a novel reversible inhibitor, BLU-945, that shows promising activity against different resistance mutations. Clinical trials are currently underway to evaluate its efficacy and safety.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Oncology
Bobbie J. Rimel, Erin K. Crane, June Hou, John Nakayama, Jennifer MacDonald, Kathleen Lutz, Vicky Makker, Roisin E. O'Cearbhaill
Summary: This article reviews the applications of oral tyrosine kinase inhibitors (TKIs) in gynecologic malignancies and summarizes the common adverse events associated with these drugs and their management strategies. TKIs have the potential to improve response rates and provide durable responses in certain patients. However, drug-related toxicity requires careful attention and management.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Chemistry, Medicinal
Hajer AlRasheed, Aliyah Almomen, Haya I. Aljohar, Maria Arafah, Rana Y. Almotawa, Manal A. Alossaimi, Nourah Z. Alzoman
Summary: This study evaluated the influence of aspartame on the pharmacokinetics of erlotinib and gefitinib in rats. The results showed that aspartame could alter the pharmacokinetic parameters of both drugs and significantly increase liver enzyme activity. Therefore, the use of aspartame-containing products should be avoided during erlotinib or gefitinib therapy.
Review
Medicine, General & Internal
Yi-Pu Zhao, Yong Long
Summary: Molecular targeted therapy has improved treatment outcomes for NSCLC patients with driver gene mutations, but it also comes with new toxicity profiles, particularly pulmonary toxicity. Prompt diagnosis of drug-induced lung injury and differential diagnosis from other pulmonary diseases are critical for managing pulmonary toxicity.
CURRENT MEDICAL RESEARCH AND OPINION
(2022)
Article
Medicine, Research & Experimental
Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen Frye, Madhusmita Behera, Frank Schneider, Suresh S. Ramalingam, Taofeek Owonikoko, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Summary: Acquired resistance is inevitable in non-small cell lung cancers (NSCLCs) treated with osimertinib (OSI). Activation of MERTK is associated with OSI resistance and inhibition of MERTK kinase can resensitize resistant cells to OSI.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Multidisciplinary Sciences
Liangkun You, Xinnan Zheng, Danchen Deng, Hongming Pan, Weidong Han
Summary: Patients with EGFR L858R mutation treated with anti-angiogenic therapy had a significantly prolonged overall survival compared to those who had not received the treatment. The therapy also showed potential to improve overall survival in patients with liver and brain metastases.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Robin Guo, Michael Offin, A. Rose Brannon, Jason Chang, Andrew Chow, Lukas Delasos, Jeffrey Girshman, Olivia Wilkins, Caroline G. McCarthy, Alex Makhnin, Christina Falcon, Kerry Scott, Yuan Tian, Fabiola Cecchi, Todd Hembrough, Deepu Alex, Ronglai Shen, Ryma Benayed, Bob T. Li, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Natasha Rekhtman, Paul Paik, Ahmet Zehir, Alexander Drilon
Summary: In MET exon 14-altered lung cancers treated with a MET TKI, the genomic mechanisms of primary resistance remain unknown, while MET expression is correlated with treatment benefit.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Kai Li, Zi-Yang Peng, Shan Gao, Qing-Shi Wang, Rui Wang, Xiang Li, Guo-Dong Xiao, Jing Zhang, Hong Ren, Shou-Ching Tang, Xin Sun
Summary: The study revealed that m6A controlled the interference of EMT features, the miR-146a/Notch signaling pathway was highly activated in an m6A-dependent manner, and TUSC7 regulation of miR-146a affected Notch signaling functions, influencing lung cancer progression and stem cell renewal.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Jung Hee Cho, Yeon-Mi You, Han Koo, Dong Chul Lee, Young Il Yeom, Kyung Chan Park
Summary: This study identified LPIN1 as a key factor in regulating gefitinib resistance in EGFR-mutant NSCLC cells, and found that LPIN1 expression was induced following gefitinib treatment, leading to increased lipid droplet formation and activation of protein kinase C delta and nuclear factor kappa B. Targeting LPIN1 was shown to synergistically inhibit tumor growth, suggesting a potential effective strategy for preventing TKI resistance in NSCLC patients.
Review
Oncology
Anjali Kalra, Sawsan Rashdan
Summary: Recent advances in non-small cell lung cancer (NSCLC) therapies have revolutionized the treatment regimens. Molecular targeted treatments like tyrosine kinase inhibitors (TKIs) prevent tumor progression and improve survival. However, the use of immune checkpoint inhibitors (ICIs) in NSCLC tumors with a driver mutation has been debated. Trials investigating the combination of these therapies with TKIs were halted due to concerns of increased toxicity.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
James Chih-Hsin Yang, Yuichiro Ohe, Chao -Hua Chiu, Xiaoling Ou, Mireille Cantarini, Pasi A. Janne, Ryan J. Hartmaier, Myung Ju Ahn
Summary: The combination of osimertinib and selumetinib showed promising antitumor activity and tolerability in patients with MET-negative, EGFRm advanced NSCLC who had progressed on previous EGFR-TKI treatment.
CLINICAL CANCER RESEARCH
(2022)
Article
Cell Biology
Pinar Ozden Eser, Raymond M. Paranal, Jieun Son, Elena Ivanova, Yanan Kuang, Heidi M. Haikala, Ciric To, Jeffrey J. Okoro, Kshiti H. Dholakia, Jihyun Choi, Yoonji Eum, Atsuko Ogino, Pavlos Missios, Dalia Ercan, Man Xu, Michael J. Poitras, Stephen Wang, Kenneth Ngo, Michael Dills, Masahiko Yanagita, Timothy Lopez, Mika Lin, Jeanelle Tsai, Nicolas Floch, Emily S. Chambers, Jennifer Heng, Rana Anjum, Alison D. Santucci, Kesi Michael, Alwin G. Schuller, Darren Cross, Paul D. Smith, Geoffrey R. Oxnard, David A. Barbie, Lynette M. Sholl, Magda Bahcall, Sangeetha Palakurthi, Prafulla C. Gokhale, Cloud P. Paweletz, George Q. Daley, Pasi A. Janne
Summary: Some EGFR-mutant, MET-amplified lung cancers may develop dependence on MET activation alone, suggesting that these patients could be treated with a single-agent MET TKI instead of the current standard-of-care EGFR and MET inhibitor combination regimens.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Review
Oncology
Carolina Gabay, Alessandro Russo, Luis E. Raez, Christian Rolfo Cervetto
Summary: The standard of care in early-stage NSCLC is surgical resection, but adjuvant chemotherapy has low 5-year overall survival rates. Tailored strategies have become the norm in advanced NSCLC, with EGFR mutated populations being common druggable molecular drivers. The use of EGFR tyrosine kinase inhibitors as adjuvant therapy is emerging, with the hope of preventing recurrences and increasing survival in early-stage NSCLC.
EXPERT REVIEW OF ANTICANCER THERAPY
(2021)
Article
Oncology
R. Donald Harvey, Kathryn F. Mileham, Vishal Bhatnagar, Jamie R. Brewer, Atiqur Rahman, Cassadie Moravek, Andrew S. Kennedy, Elizabeth A. Ness, E. Claire Dees, S. Percy Ivy, Scot W. Ebbinghaus, Caroline Schenkel, Thomas S. Uldrick
Summary: This study highlights the inconsistency and lack of scientific rationale behind washout periods and concomitant medication exclusions in cancer clinical trial protocols. Arbitrary or blanket exclusions should be eliminated, and clinically relevant eligibility criteria may be included based on evidence.
CLINICAL CANCER RESEARCH
(2021)
Correction
Genetics & Heredity
Yuan Yuan, Young Seok Ju, Youngwook Kim, Jun Li, Yumeng Wang, Christopher J. Yoon, Yang Yang, Inigo Martincorena, Chad J. Creighton, John N. Weinstein, Yanxun Xu, Leng Han, Hyung-Lae Kim, Hidewaki Nakagawa, Keunchil Park, Peter J. Campbell, Han Liang
Correction
Genetics & Heredity
Yuan Yuan, Young Seok Ju, Youngwook Kim, Jun Li, Yumeng Wang, Christopher J. Yoon, Yang Yang, Inigo Martincorena, Chad J. Creighton, John N. Weinstein, Yanxun Xu, Leng Han, Hyung-Lae Kim, Hidewaki Nakagawa, Keunchil Park, Peter J. Campbell, Han Liang
Summary: A revised version of this paper has been published and can be accessed through a link at the top.
Article
Oncology
Keunchil Park, Gee-Chen Chang, Giuseppe Curigliano, Wan-Teck Lim, Ross A. Soo, Miguel A. Molina-Vila, Valerie Cattan, Helene Darville, Eric Gandossi, Veronika Smutna, Isabelle Sudey, Santiago Viteri
Summary: The combination of gefitinib with S49076 showed limited anti-tumour activity with good tolerability in EGFR TKI-resistant NSCLC patients. The study did not reveal a clear trend in activity within specific molecular subsets due to the small number of eligible patients.
Article
Oncology
Hongsik Kim, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun
Summary: Plasma EGFR mutation tests are commonly used for NSCLC patients developing resistance to EGFR inhibitors. This study found that the detection rate of T790M in subsequent tests was influenced by the presence of sensitizing mutations in initial plasma tests. The low sensitivity of the plasma test for T790M suggests the need for follow-up tissue or plasma tests.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Oncology
Sehhoon Park, Steve Olsen, Bo Mi Ku, Min-Sang Lee, Hyun-Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon-La Choi, Myung-Ju Ahn
Summary: This study analyzed the concordance of actionable genomic alterations in non-small cell lung cancer patients detected through circulating tumor DNA (ctDNA) and tissue sequencing. The results showed that ctDNA testing can identify additional actionable genomic alterations beyond tissue testing.
Review
Oncology
Edward S. Kim, Barbara Melosky, Keunchil Park, Nobuyuki Yamamoto, James C-H Yang
Summary: Data comparing outcomes of different EGFR tyrosine kinase inhibitors in Asian patients with EGFR mutation-positive non-small-cell lung cancer are limited. While first- and second-generation TKIs show similar outcomes in Asian and non-Asian populations, the third-generation TKI osimertinib does not confer the same overall survival benefit in Asians, particularly in well-resourced countries like Japan. Head-to-head comparisons of second- and third-generation EGFR TKIs should be considered in Asia.
Article
Oncology
Salma K. Jabbour, Ki Hyeong Lee, Nikolaj Frost, Valeriy Breder, Dariusz M. Kowalski, Theodore Pollock, Evgeny Levchenko, Noemi Reguart, Alex Martinez-Marti, Baerin Houghton, Jean-Baptiste Paoli, Sufia Safina, Keunchil Park, Takefumi Komiya, Amy Sanford, Vishal Boolell, Hong Liu, Ayman Samkari, Steven M. Keller, Martin Reck
Summary: The study suggests promising antitumor activity of pembrolizumab plus cCRT and manageable safety in patients with previously untreated, locally advanced, stage III NSCLC.
Article
Oncology
Antonio Passaro, Filippo de Marinis, Hai-Yan Tu, Konstantin K. Laktionov, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Eng Huat Tan, Maya Gottfried, Victor Lee, Dariusz Kowalski, Cheng Ta Yang, B. J. Srinivasa, Laura Clementi, Tejaswini Jalikop, Dennis Chin Lun Huang, Agnieszka Cseh, Keunchil Park, Yi-Long Wu
Summary: The study demonstrates that afatinib was well tolerated and showed promising efficacy in treating EGFR-TKI-naive patients with EGFRm+ NSCLC, including those with brain metastases or uncommon EGFR mutations. Treatment-related adverse events were common, with diarrhea and rash being the most frequent. The results suggest that afatinib may be a valuable treatment option for this patient population.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
D. Ross Camidge, Teresa Moran, Ingel Demedts, Heidrun Grosch, Kathryn Mileham, Julian Molina, Oscar Juan-Vidal, Gerold Bepler, Jonathan W. Goldman, Keunchil Park, Johan Wallin, Sameera R. Wijayawardana, Xuejing Aimee Wang, Volker Wacheck, Egbert Smit
Summary: This Phase II study examined the use of emibetuzumab to overcome acquired resistance to erlotinib in NSCLC patients with high MET protein expression levels. The study found that emibetuzumab did not effectively reverse resistance to erlotinib, although some patients experienced clinical benefit.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Remi Veillon, Hiroshi Sakai, Xiuning Le, Enriqueta Felip, Alexis B. Cortot, Egbert F. Smit, Keunchil Park, Frank Griesinger, Christian Britschgi, Yi-Long Wu, Barbara Melosky, Shobhit Baijal, Gilberto de Castro Jr, Michaela Sedova, Karin Berghoff, Gordon Otto, Paul K. Paik
Summary: The study demonstrated the safety and tolerability of tepotinib in patients with MET exon 14 skipping non-small cell lung cancer. Adverse events were mostly mild/moderate and manageable, with few withdrawals.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Yuichiro Doki, Makoto Ueno, Chih-Hung Hsu, Do-Youn Oh, Keunchil Park, Noboru Yamamoto, Tatsuya Ioka, Hiroki Hara, Manabu Hayama, Masahiro Nii, Keiko Komuro, Mariko Sugimoto, Makoto Tahara
Summary: This study evaluated the safety, tolerability, and antitumor activity of durvalumab monotherapy and durvalumab plus tremelimumab combination therapy in Asian patients with biliary tract cancer, esophageal squamous cell carcinoma, or head and neck squamous cell carcinoma. The results demonstrated acceptable safety profiles and clinical benefit in these patients.
Article
Oncology
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, Pascale Tomasini, Filippo de Braud, Benjamin J. Solomon, Daniel Shao-Weng Tan, Guzman Alonso, Juergen Wolf, Keunchil Park, Koichi Goto, Victoria Soldatenkova, Sylwia Szymczak, Scott S. Barker, Tarun Puri, Aimee Bence Lin, Herbert Loong, Benjamin Besse
Summary: In this study, selpercatinib demonstrated durable and robust responses in both previously treated and treatment-naive patients with RET fusion-positive NSCLC, including intracranial activity.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Hyun Ae Jung, Jinyeong Lim, Yoon-La Choi, Jhingook Kim, Keunchil Park
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Byoung Chul Cho, Herbert H. F. Loong, Chun-Ming Tsai, Man Lung P. Teo, Hye Ryun Kim, Sun Min Lim, Suyog Jain, Steve Olsen, Keunchil Park
Summary: Plasma-based next-generation sequencing provides timely and clinically informative mutational genomic profiling for advanced non-squamous NSCLC in East Asian patients.
Correction
Oncology
Makoto Nishio, Takashi Seto, Martin Reck, Edward B. Garon, Chao-Hua Chiu, Kiyotaka Yoh, Fumio Imamura, Keunchil Park, Jin-Yuan Shih, Carla Visseren-Grul, Bente Frimodt-Moller, Annamaria Zimmermann, Gosuke Homma, Sotaro Enatsu, Kazuhiko Nakagawa